Prenetics CEO buys 20,000 PRE shares in $260K open-market deal

Prenetics Global Limited reported that its Chief Executive Officer and co‑founder, Danny Sheng Wu Yeung, bought additional shares of the company in the open market.

Rhea-AI Filing Summary

Prenetics Global Limited reported that its Chief Executive Officer and co‑founder, Danny Sheng Wu Yeung, bought additional shares of the company in the open market. On November 19, 2025, he purchased 20,000 Class A Ordinary Shares at $13.00 per share, for a total purchase price of $260,000. Following this transaction, his total holdings of Class A Ordinary Shares increased to 96,412 shares. This reflects a personal capital commitment by the CEO using his own funds rather than an issuance of new shares by the company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Prenetics Global Limited (PRE) announce in this Form 6-K?

Prenetics Global Limited announced that its Chief Executive Officer and co-founder, Danny Sheng Wu Yeung, purchased 20,000 Class A Ordinary Shares of the company in the open market.

How many Prenetics (PRE) shares did the CEO buy and at what price?

The CEO bought 20,000 Class A Ordinary Shares at a price of $13.00 per share, for a total purchase price of $260,000.

What is the CEO’s total shareholding in Prenetics (PRE) after this purchase?

After the transaction, Danny Sheng Wu Yeung holds a total of 96,412 Class A Ordinary Shares of Prenetics Global Limited.

Was this Prenetics (PRE) share purchase an open market transaction?

Yes. The filing states that the 20,000 Class A Ordinary Shares were purchased in the open market at a price of $13.00 per share.

Does Prenetics receive any proceeds from the CEO’s share purchase?

No. The transaction described is a personal open market purchase by the CEO, so the $260,000 purchase price was paid to market sellers, not to the company.

Who signed the Prenetics (PRE) Form 6-K related to the CEO’s share purchase?

The Form 6-K was signed on behalf of Prenetics Global Limited by Lo Hoi Chun, the company’s Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/20/2025 - 07:57 AM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number 001-41401

Prenetics Global Limited

11401 Granite St. Charlotte, NC 28273 USA Unit 703-706, K11 Atelier 728 King’s Road, Quarry Bay Hong Kong

(Addresses of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  Form 20-F  Form 40-F 

EXPLANATORY NOTE

Prenetics Global Limited (the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, furnishes this Form 6-K to announce that on November 19, 2025 its Chief Executive Officer and co-founder, Danny Sheng Wu Yeung, purchased 20,000 shares of the Company's Class A Ordinary Shares at a price of $13.00 per share in the open market for a total purchase price of $260,000, bringing his total holdings of Class A Ordinary Shares to 96,412.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Prenetics Global Limited
			By:			/s/ Lo Hoi Chun
			Name:			Lo Hoi Chun
			Title:			Chief Financial Officer
Date: November 20, 2025